Early Alzheimer'
Conditions
Interventions
None listed
Sponsors
St. Marianna University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients clinically diagnosed with probable Alzheimer's disease dementia or MCI due to Alzheimer's disease at participating institutions between the ethics approval date and March 31, 2027. Patients who underwent amyloid PET and were confirmed positive. Patients for whom intravenous treatment with lecanemab or donanemab has been determined to be appropriate by the attending physician. Patients who have provided written informed consent, either directly or via a legally authorized representative. Age between 50 and 90 years.
Exclusion criteria
Exclusion criteria: - Patients whose amyloid PET result was negative at the baseline evaluation - Patients diagnosed with mild cognitive impairment or dementia due to other neurodegenerative diseases or medical conditions - Patients deemed unsuitable for participation in this study by the attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MacCATT total score and its association with clinical variables (cognitive function, neuropsychiatric symptoms, psychological loneliness, ADL, MRI findings, amyloid PET findings). | — |
Secondary
| Measure | Time frame |
|---|---|
| Associations between MacCATT subscale scores and amyloid PET parameters (SUVR, composite SUVR, centiloid, asymmetry index). Longitudinal changes in treatment decision-making capacity at 6, 12, and 18 months and their associations with clinical variables. | — |
Countries
Japan
Contacts
Public ContactKoji Kasanuki
St. Marianna Universitiy School of Medicine Department of Neuropsychiatry
Outcome results
None listed